Myelofibrosis 2023 Snapshot: Key Numbers, Players, and Pipeline Drugs

Health Apr 24, 2025 20 Add to Reading List

Myelofibrosis (MF) is a rare and progressive type of blood cancer where scar tissue builds up in the bone marrow, interfering with the body’s ability to produce healthy blood cells. It is part of a larger category known as myeloproliferative neoplasms (MPNs), which are defined by abnormal cell growth in the bone marrow. Primary MF refers to cases that arise on their own, while secondary MF develops from pre-existing blood disorders such as polycythemia vera (PV) or essential thrombocythemia (ET)—often termed post-PV or post-ET MF.

Epidemiology of Myelofibrosis (2020–2034) in the 7MM

Epidemiological research across the seven major markets (7MM) examines MF prevalence using the following segmentation:

Total and Diagnosed Prevalent Population
Type-Specific Prevalence
Risk Stratification
Age-Based Distribution
Genetic Profiles (e.g., JAK2 mutations)
Transplant Eligibility

Noteworthy Insights:

Around 56,000 individuals were living with MF across the 7MM in 2023, with case numbers anticipated to rise by 2034.
Among the EU4 and the UK, Germany had the highest diagnosed prevalence, while the UK had the lowest.
In the U.S., most diagnosed cases in 2023 were considered high-risk.
Primary MF made up roughly 75% of total U.S. cases.
The 70+ age group accounted for the largest segment, totaling nearly 12,000 patients.
JAK2 mutations were found in approximately 60% of U.S. cases.

View the full epidemiological breakdown in this Myelofibrosis Infographic.

Myelofibrosis Market Overview

In 2023, the Myelofibrosis market size across the 7MM reached an estimated USD 1.8 billion, driven by evolving treatment options and growing disease awareness.

Key Growth Drivers:

OMJJARA has gained approval for both first-line and previously treated patients, giving it an edge in the treatment landscape.
VONJO’s approval for use in patients with low platelet counts has addressed an unmet need within a specific subgroup.

Challenges in the Market:

Diagnosing MF can be complex due to symptom overlap with other fibrotic diseases like idiopathic pulmonary fibrosis.
The therapeutic space is crowded, with several emerging drugs vying for market share with promises of disease-modifying potential.

For an in-depth look at commercial trends and forecasts, check out the Myelofibrosis Market Report.